Real-World Experience of Efficacy and Safety of Baricitinib in Korean Patients with Severe Alopecia Areata

This retrospective analysis evaluated the efficacy and safety of baricitinib 4 mg in 38 Korean patients with severe alopecia areata (AA) over a minimum of 6 months. The study included patients with a Severity of Alopecia Tool (SALT) score of 50 or higher, with a mean baseline SALT score of 95.21 ± 10.46. At week 24, 34.21% of patients achieved a SALT score of ≤ 20. Additionally, 48% and 47.6% of patients showed a ≥ 2-point improvement in Clinician-Reported Outcome (ClinRO) Measure for Eyebrow and Eyelash Hair Loss, respectively. Common adverse events included creatine phosphokinase elevation, acne, and lipid level elevation. The findings suggest that baricitinib 4 mg is effective and safe for treating severe AA, including alopecia totalis and universalis.